US 11,753,632 B2
Highly potent acid alpha-glucosidase with enhanced carbohydrates
Russell Gotschall, Doylestown, PA (US); and Hung V. Do, New Hope, PA (US)
Assigned to Amicus Therapeutics, Inc., Philadelphia, PA (US)
Filed by Amicus Therapeutics, Inc., Philadelphia, PA (US)
Filed on Feb. 23, 2021, as Appl. No. 17/249,175.
Application 17/249,175 is a division of application No. 16/252,505, filed on Jan. 18, 2019, granted, now 10,961,522.
Application 16/252,505 is a continuation of application No. 15/515,808, granted, now 10,208,299, issued on Feb. 19, 2019, previously published as PCT/US2015/053252, filed on Sep. 30, 2015.
Claims priority of provisional application 62/135,345, filed on Mar. 19, 2015.
Claims priority of provisional application 62/112,463, filed on Feb. 5, 2015.
Claims priority of provisional application 62/057,842, filed on Sep. 30, 2014.
Claims priority of provisional application 62/057,847, filed on Sep. 30, 2014.
Prior Publication US 2021/0261935 A1, Aug. 26, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/40 (2006.01); A61K 48/00 (2006.01); C12N 15/09 (2006.01)
CPC C12N 9/2465 (2013.01) [A61K 48/005 (2013.01); C12N 15/09 (2013.01); C12Y 302/0102 (2013.01); C12N 2510/02 (2013.01)] 19 Claims
 
1. A method for metabolizing, degrading, removing, or decreasing glycogen in tissue, muscle, muscle fiber, muscle cells, lysosomes, organelles, cellular compartments, or cytoplasm of a cell in a subject in need thereof, wherein the method comprises administering to the subject a composition comprising recombinant human acid alpha-glucosidase (rhGAA) produced from Chinese hamster ovary (CHO) cells, wherein 40%-60% of the N-glycans on the rhGAA are complex type N-glycans and the rhGAA comprises 3.0-6.0 mol mannose-6-phosphate (M6P) per mol rhGAA.